Median Technologies Announces Completion of the Q-Submission Phase with the FDA for its iBiopsy Lung Cancer Screening CADe/CADx Software as Medical Device

Median Technologies announces  that the Company has received feedback from the United States Food and Drug Administration (FDA) regarding the Q-submission phase initiated on May 2, 2022 for its iBiopsy Lung Cancer Screening (LCS) AI/ML tech-based CADe/CADx¹ Software as Medical Device (SaMD) and announces completion of this phase.

Recommended AI: Cognni Launches AI-Powered Automated Infosec Risk Assessment Product

The Q-submission phase is a major regulatory step which allows regular and in-depth discussions with the FDA on key topics such as pivotal study protocols. Further to this Q-submission phase, Median’s SaMD is better tailored to fit the FDA’s expectations and market needs.

As next steps, Median Technologies, having finalized its pivotal study protocols, is now getting ready for pivotal study execution by the end of Q2 2023, as planned, once all imaging and clinical data collection and preparation as well as reader training are completed. Likewise, Median still targets obtaining the FDA 510(k) clearance for its iBiopsy LCS CADe/CADx SaMD in the first half of 2024, subject to FDA review requirements.

Recommended AI: AI Smart Chain Ecosystem Launches, Bringing Artificial Intelligence to Crypto Space

“The Q-submission phase allowed us to have frequent and fruitful interactions with the Agency in order to better tailor our medical device software to the US market”, Fredrik Brag, CEO and Founder of Median Technologies said. “But more than that, we had the opportunity to present to the FDA the vision we have for our product, the cutting edge performance we aim for, and our ambition to change the paradigm in the early diagnosis of lung cancer patients”, Brag added.

Recommended AI: SAS Joins CESMII to Accelerate the Adoption of Analytics and AI

[To share your insights with us, please write to sghosh@martechseries.com]